LTC and Compounding Pharmacy, 2001-Vintage Ohio Family Operation

$11.6M

Revenue

$4.5M

SDE

4.0x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a two-location Ohio pharmacy business built around two durable, less-commoditized niches: long-term care (LTC) dispensing and non-sterile compounding. Founded in 2001, it has run for over two decades as a family operation and generates roughly $11.6M in revenue with $4.5M in EBITDA, a fat 39 percent margin that tells you this is not a retail counter fighting Amazon and CVS on generic scripts. LTC pharmacies serve nursing homes, assisted living facilities, and group homes on recurring, contract-based dispensing, while compounding produces customized medications that carry pricing power and stickier relationships.

The revenue mix is the entire story here. Retail pharmacy is a brutal business getting squeezed by PBMs and reimbursement compression, but LTC and compounding are structurally better: recurring facility contracts, embedded switching costs, and margins that reflect specialization rather than commodity fill volume. A 39 percent EBITDA margin on $11.6M is exceptional for the sector and signals the mix leans heavily on the higher-value work rather than front-of-store retail.

The seller is retiring and states a management team is already in place, which matters enormously for an $18M asking price. The buildings are leased (12,000 SF at $9,500/month through August 2032), so this is a pure operating-business acquisition with no real estate padding the multiple. At 4x EBITDA for a defensible, recurring-revenue healthcare cash flow, the headline multiple looks reasonable if the earnings and contracts hold up under scrutiny.

Why we like it

The earnings quality is genuinely strong on paper: $4.5M EBITDA on $11.6M revenue is a 39 percent margin, which for a pharmacy signals the mix is weighted toward high-value compounding and contracted LTC rather than commodity retail fills. That kind of margin is rare in a sector where PBM reimbursement crushes standard retail pharmacies. The recurring nature of LTC facility contracts underpins the profit.
The moat sits in the business model, not the brand. LTC dispensing is contract-based, high-touch, and heavily regulated, which creates real switching costs for the nursing homes and assisted living facilities it serves. Compounding adds a specialized capability that most retail pharmacies cannot replicate, giving pricing power and stickier physician and patient relationships.
Demographic tailwinds are as durable as they come. An aging US population feeds continuous demand for long-term care pharmacy services, and this is spend that does not get cut in a recession because it serves patients in facilities who need daily medication regardless of the economy. Healthcare and prescription drugs are among the last line items households and facilities cut.
The operator advantage is that a management team is already in place and the seller is retiring, which means a buyer is inheriting a running machine rather than a job. At 4x a $4.5M EBITDA on a business founded in 2001, this is a mature, proven cash flow with over two decades of operating history behind it. That reduces execution risk for a financial or strategic buyer.

How to improve it

Audit the payer and PBM contract mix in the first 90 days and quantify reimbursement exposure by line of business. Understanding which revenue comes from LTC facility contracts versus compounding versus retail lets you protect the high-margin work and prune anything getting squeezed on reimbursement. This directly defends the 39 percent margin that justifies the price.
Expand the LTC facility footprint by adding contracts with nearby nursing homes, assisted living communities, and group homes. Each new facility is recurring, contracted volume that leverages existing dispensing infrastructure and pharmacist labor, driving incremental margin. This is the clearest organic growth lever given the demographic demand.
Grow the compounding book by deepening physician referral relationships and adding therapeutic categories where demand is under-served locally. Compounding carries pricing power that retail dispensing does not, so shifting mix further toward it lifts blended margin. Track script counts and margins by compound to double down on the winners.
Formalize the management team roles and lock in key personnel with retention agreements before close. Since the seller is retiring and the team runs the business, the entire thesis rests on that team staying. Retention bonuses and clear succession planning protect the earnings you are paying 4x for.
Invest in dispensing technology and workflow automation to increase script capacity without proportional labor cost. LTC pharmacies benefit heavily from packaging automation and eMAR integration with facilities, which improves margins and makes the pharmacy stickier with its facility clients. This is a defensive and offensive move at once.
Renegotiate or extend the facility lease strategically given the August 2032 expiration. At $9,500 per month for 12,000 SF the rent is modest, so locking in favorable long-term terms or an early renewal removes a future cost variable and protects the buyer from relocation disruption to a licensed, regulated pharmacy facility.

Diligence notes

Verify the 39 percent EBITDA margin with tax returns and reconcile it against the revenue breakdown by segment. A margin this high for a pharmacy is exceptional and demands scrutiny: confirm it is not inflated by owner add-backs, a temporary reimbursement window, or a single lucrative compound or facility contract. The entire $18M valuation depends on this number being real and durable.
Examine LTC facility contract terms, tenure, and concentration. If a large share of revenue flows from one or two nursing home groups, the loss of a single contract could meaningfully impair EBITDA. Review contract expiration dates, renewal terms, and the relationship history to gauge stickiness.
Scrutinize the compounding operation for regulatory and licensing risk. Non-sterile compounding is regulated at the state board and USP level, and any pending inspection issues, 503A compliance gaps, or DEA concerns could create liability or disrupt operations. Confirm all pharmacy licenses, DEA registrations, and accreditations transfer cleanly.
Assess the strength and stability of the management team since the seller is retiring and the team runs the business. Identify the pharmacist-in-charge, key relationships, and any single points of failure, then confirm they intend to stay post-close. Interview them directly and structure retention before signing.
Confirm reimbursement trend lines and PBM exposure across the payer mix. Pharmacy reimbursement is under constant pressure, so review the last several years of gross margin per script by segment to detect any erosion that could compound after close. A declining reimbursement trajectory would undercut the 4x multiple.

Source

Originally listed on BizBuySell. View original listing →